ESC European Society of Cardiology

European Journal of Preventive Cardiology (2025) **32**, 905–907
https://doi.org/10.1093/eurjpc/zwae367

RAPID COMMUNICATIONS
Cardiac rehabilitation

Setting the exercise intensity in cardiovascular rehabilitation for patients with cardiometabolic disease: is it different between males and females?

Juliana Goulart Prata Oliveira Milani [1,2], Mauricio Milani [1,2,3], Felipe Vilaça Cavallari Machado [1,3,4], Matthias Wilhelm [5], Thimo Marcin [5], Flavio D'Ascenzi [6], Luna Cavigli [6], Charly Keytsman [3], Maarten Falter [3,7,8], Fabrício Braga [9,10], Anderson Donelli da Silveira [11,12], Graziella França Bernardelli Cipriano [2,13], Veronique Cornelissen [14], Kenneth Verboven [1,4], Gerson Cipriano Junior [2,15†], and Dominique Hansen [1,3,4*†]

[1]Rehabilitation Research Center (REVAL), Faculty of Rehabilitation Sciences, Hasselt University, Wetenschapspark 7, Diepenbeek 3590, Belgium; [2]Graduate Programme in Health Sciences and Technologies, University of Brasilia (UnB), Brasilia, DF, Brazil; [3]Heart Centre Hasselt, Jessa Hospital, Stadsomvaart 11, Hasselt 3500, Belgium; [4]Faculty of Medicine and Life Sciences, Biomedical Research Institute (BIOMED), Hasselt University, Gebouw C, Diepenbeek 3590, Belgium; [5]Centre for Rehabilitation & Sports Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; [6]Department of Medical Biotechnologies, Sports Cardiology and Rehab Unit, University of Siena, Siena, Italy; [7]Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium; [8]Department of Cardiology, Faculty of Medicine, KU Leuven, Leuven, Belgium; [9]Laboratório de Performance Humana, Rio de Janeiro, Brazil; [10]Department of Cardiology, State University of Rio de Janeiro, Rio de Janeiro, Brazil; [11]Division of Cardiology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; [12]Postgraduate Program in Cardiology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil; [13]Rehabilitation Sciences Programme, University of Brasilia (UnB), Brasilia, DF, Brazil; [14]Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium; and [15]Graduate Program in Human Movement and Rehabilitation of Evangelical (PPGMHR), UniEVANGÉLICA, Anápolis, Brazil

Received 10 June 2024; revised 22 September 2024; accepted 25 October 2024; online publish-ahead-of-print 5 November 2024

Contemporary cardiovascular research increasingly considers sex as a biological variable in exercise prescription to better comprehend physiological differences and develop tailored plans, optimizing cardiovascular health and outcomes for both men and women.[1,2] This is important as exercise prescription should not follow 'one-size-fits-all' methodology, and emerging evidence of sex-related differences in exercise responses—due to anatomical and physiological characteristics—may affect oxygen transport, utilization, and fatigue resistance in both acute and chronic exercise.[3]

In cardiovascular rehabilitation and for healthy individuals, ventilatory thresholds (VTs) obtained by cardiopulmonary exercise test (CPET) are preferred for exercise intensity prescription over peak effort percentages like heart rate (%HR_{peak}) or oxygen uptake (%VO_{2peak}).[4,5] However, when CPET is unavailable, guidelines recommend using peak effort indices [e.g. %HR_{peak} or percentage of peak cycle ergometre load (%W_{peak})].[4,6]

Nevertheless, recent observations indicate that, at least in healthy individuals, the lactate threshold occurs at a higher %VO_{2peak} and %HR_{peak} in women compared to men.[5] This underscores the limitations of current exercise prescription methods based on these metrics, potentially failing to regulate the metabolic stimulus needed for equivalent training adaptations. Thomas *et al.*[7] found that fixed VO_{2peak} percentages (60–90%) improved exercise capacity similarly across sexes. However, the commonly observed lower baseline VO_{2peak} in females raises concerns about exercise stimulus equivalence.

Hence, uncertainties remain as to whether males and females experience similar levels of metabolic stimulus based on the domain schema, particularly in patients with cardiometabolic diseases (CMDs).[1,3]

Therefore, this study aims to compare physiological responses [%VO_{2peak}, %HR_{peak}, percentage of heart rate reserve (%HRR), or %W_{peak} at the first and second VTs (VT_1 and VT_2)] between females and males with CMDs. We hypothesize that these differences exist, may influence exercise prescription recommendations, and require sex-specific ranges to properly control the metabolic stimulus.

We analysed 3269 CPETs from 12 centres across 9 countries (9 in Europe and 3 in South America) for VTs and their correlation with %VO_{2peak}, %HR_{peak}, %HRR, and %W_{peak}. Our retrospective study used data from prior prospective studies, approved by all relevant ethics committees (see Supplementary material).

The inclusion criteria comprised individuals aged ≥20 years with a peak respiratory exchange ratio above 1.00 and without pulmonary,

* Corresponding author. Tel: +32 11 26 80 97, Email: dominique.hansen@uhasselt.be
† The last two authors shared senior author position.

Table 1 Cardiopulmonary exercise test variables by sexes and ergometres

	Cycle ergometre			Treadmill		
CPET variables	**Female ($n = 351$)**	**Male ($n = 1410$)**	***P*-value**	**Female ($n = 350$)**	**Male ($n = 1158$)**	***P*-value**
VO_{2peak}, L/min	1.16 (0.96, 1.39)	1.67 (1.32, 2.07)	<0.001	1.11 (0.91, 1.36)	1.85 (1.41, 2.31)	<0.001
VO_{2peak}, mL/kg/min	16.4 (14.1, 19.9)	20.1 (16.4, 25.0)	<0.001	16.9 (14.3, 20.1)	22.1 (17.7, 28.0)	<0.001
RER_{peak}	1.12 (1.09, 1.20)	1.13 (1.10, 1.20)	0.138	1.16 (1.11, 1.23)	1.18 (1.11, 1.25)	0.009
HR_{peak}, b.p.m.	124 (109, 146)	128 (111, 146)	0.100	136 (117, 152)	142 (123, 160)	<0.001
HR_{peak}, % predicted	76.8 (68.1, 88.8)	79.5 (69.8, 89.5)	0.07	80.6 (70.7, 88.9)	85.0 (75.0, 94.3)	<0.001
HR_{rest}, b.p.m.	69 (62, 80)	68 (60, 76)	0.002	71 (63, 82)	68 (61, 76)	<0.001
HRR, b.p.m.	55 (41, 73)	60 (44, 76)	0.002	62 (46, 78)	72 (54, 90)	<0.001
Peak load (W_{peak})	90 (72, 114)	137 (107, 176)	<0.001	—	—	—
Peak speed (km/h)	—	—	—	5.9 (5.2, 6.7)	7.1 (6.0, 8.8)	<0.001
Peak inclination (%)	—	—	—	6.5 (5.0, 8.0)	5.0 (3.5, 7.0)	<0.001
VO_2 at VT_1, mL/kg/min	10.3 (8.7, 12.2)	11.6 (9.8, 13.9)	<0.001	10.9 (9.5, 12.6)	12.9 (11.1, 15.3)	<0.001
VO_2 at VT_1, $\%VO_{2peak}$	62.8 (55.0, 68.9)	58.4 (51.3, 65.7)	<0.001	65.2 (59.3, 71.7)	59.3 (52.6, 66.5)	<0.001
HR at VT_1, b.p.m.	92 (83, 105)	92 (83, 103)	0.297	96 (89, 106)	98 (88, 109)	0.656
HR at VT_1, $\%HR_{peak}$	76.0 (68.8, 81.7)	73.4 (66.4, 79.5)	<0.001	74.0 (66.7, 79.8)	70.2 (64.8, 76.8)	<0.001
HR at VT_1, %HRR	41.9 (33.3, 52.5)	40.0 (31.3, 50.6)	0.033	41.3 (32.9, 49.4)	40.3 (33.3, 48.5)	0.467
Load at VT_1, *W*	39 (29, 51)	60 (47, 81)	<0.001	—	—	—
Load at VT_1, $\%W_{peak}$	44.1 (36.0, 53.3)	45.3 (37.8, 53.7)	0.166	—	—	—
Speed at VT_1 (km/h)	—	—	—	3.9 (3.2, 4.6)	4.9 (4.0, 5.7)	<0.001
Inclination at VT_1 (%)	—	—	—	2.5 (2.0, 3.0)	2.0 (1.5, 3.0)	<0.001
VO_2 at VT_2, mL/kg/min	14.4 (12.2, 17.2)	16.6 (13.7, 20.6)	<0.001	15.3 (13.0, 17.9)	19.8 (15.8, 25.2)	<0.001
VO_2 at VT_2, $\%VO_{2peak}$	86.9 (81.8, 90.8)	84.2 (78.9, 89.4)	<0.001	90.9 (86.7, 95.2)	90.6 (85.8, 94.8)	0.205
HR at VT_2, b.p.m.	110 (98, 127)	112 (100, 126)	0.905	122 (107, 136)	127 (110, 144)	<0.001
HR at VT_2, $\%HR_{peak}$	90.3 (86.6, 94.5)	89.1 (84.5, 93.0)	<0.001	91.7 (87.3, 95.6)	90.8 (86.8, 94.0)	0.005
HR at VT_2, %HRR	77.2 (69.0, 85.6)	75.3 (66.2, 83.6)	0.002	81.5 (72.7, 88.9)	80.6 (73.3, 87.9)	0.514
Load at VT_2, *W*	71 (57, 90)	107 (84, 138)	<0.001	—	—	—
Load at VT_2, $\%W_{peak}$	80.0 (73.3, 85.9)	78.7 (72.8, 84.6)	0.095	—	—	—
Speed at VT_2 (km/h)	—	—	—	5.4 (4.6, 6.1)	6.4 (5.4, 7.7)	<0.001
Inclination at VT_2 (%)	—	—	—	5.5 (4.0, 6.5)	4.0 (3.0, 5.5)	<0.001

Data expressed as median and IQR. Statistics: Mann–Whitney *U* test.
HR, heart rate; HRR, heart rate reserve; HR_{rest}, rest heart rate; HR_{peak}, peak heart rate; RER_{peak}, peak respiratory exchange ratio; VO_2, oxygen uptake; VO_{2peak}, peak oxygen uptake; VT_1, first ventilatory threshold; VT_2, second ventilatory threshold; $\%HR_{peak}$, percentage of peak heart rate; %HRR, percentage of heart rate reserve; $\%VO_{2peak}$, percentage of peak oxygen uptake.

neurological, or severe orthopaedic disorders. Exclusion criteria included pacemakers or implantable cardioverter devices without sinus rhythm during exercise and unidentified VTs. Patients underwent symptom-limited CPETs on cycle ergometre or treadmill with individualized ramp protocols, including breath-by-breath gas analysis and electrocardiographic monitoring. Each laboratory followed international standards for device calibration, exercise protocols, and analysis.[4,8]

Data were expressed as median and interquartile range (IQR) or absolute and relative frequency. Sex comparisons utilized Mann–Whitney *U* tests or χ^2 tests. We used multivariable linear regression with a stepwise forward algorithm to evaluate the independent effect of sex on $\%VO_{2peak}$, $\%HR_{peak}$, %HRR, and W_{peak} at VTs, ensuring assumptions were met. Predictors were selected based on background knowledge of their effects on exercise response. Thus, five independent variables were considered: sex, ergometre, age, body mass index, and beta-blocker use. First, sex was tested in a univariate model (Model 1), followed by adding ergometre (Model 2) and by multivariate analysis (Model 3). Only significant predictors remained in Model 3. If sex was not significant in Model 1, further models were not used. Analyses were performed using IBM-SPSS ($P < 0.05$).

The sample comprised 701 women and 2568 men [median ages: 63 years (IQR: 52–70) and 64 years (IQR: 54–71), respectively]. Coronary artery disease prevalence was 76.6% in males and 60.5% in females, while heart failure prevalence was 19.5 and 31.0%, respectively (see Supplementary material online, *Table S1*).

On cycle ergometre, females exhibited higher $\%VO_{2peak}$ at VT_1 (62.8% vs. 58.4%) and at VT_2 (86.9% vs. 84.2%), as well as higher $\%HR_{peak}$ at VT_1 (76.0% vs. 73.4%) and at VT_2 (90.3% vs. 89.1%), compared to males ($P < 0.001$). Additionally, females showed higher %HRR at VT_1 (41.9% vs. 40.0%, $P = 0.033$) and at VT_2 (77.2% vs. 75.3%, $P = 0.002$). However, $\%W_{peak}$ was not different (*Table 1*). On treadmill, slightly different results were observed: females showed only VT_1 at a higher $\%VO_{2peak}$ (65.2% vs. 59.3%, $P < 0.001$). Additionally, females had VTs at a higher $\%HR_{peak}$ than males (VT_1: 74.0% vs. 70.2%, $P < 0.001$; VT_2: 91.7% vs. 90.8%, $P = 0.005$), but no significant differences in %HRR (*Table 1* and Supplementary material

online, *Figures S1–S4*). Although significant sex differences were found in VTs on both ergometres, they remained below 5%, questioning their clinical relevance for distinct prescription recommendations.

The multivariable linear regression indicated that the models were weak, explaining <7% of the variation for HR-based measures and <15% for $\%VO_{2peak}$ (see Supplementary material online, *Table S2*). Most predictors had influences below 5%. Sex emerged as a significant predictor in $\%VO_{2peak}$ and $\%HR_{peak}$, although with a low magnitude effect. Notably, sex had no significant influence on $\%W_{peak}$ for both VTs, or on %HRR at VT_1. At VT_2, the ergometre influenced $\%VO_{2peak}$ and %HRR by 5–6%, yet again raising doubts about its clinical relevance despite statistical significance.

The results align with our recent findings on equations predicting HR at VTs using multiple regression analyses with exercise-derived predictors, in which sex was not included as a significant independent variable in the final models.[6,9]

Importantly, current evidence shows that no fixed percentage of peak effort consistently defines domain-specific distribution during constant work exercise, affecting exercise results and aerobic prescription frameworks.[4–6] Alternatively, prescriptions based on %HRR are more accurate than peak effort percentages.[9] Our study indicated that sex had minimal effect on %HRR at VT_2 and none at VT_1.

One limitation of this study was the lack of data on sex-specific risk factors, often undocumented but recognized as early indicators of cardiovascular risk, such as adverse pregnancy outcomes, lack of breastfeeding, early menopause, polycystic ovary syndrome, and infertility.[10] More research is required to better understand these unique sex-specific disease mechanisms.

In conclusion, while significant sex differences in $\%VO_{2peak}$ and $\%HR_{peak}$ were found, their clinical relevance appears limited. This suggests that current exercise prescription methods may not require substantial adjustments based solely on sex for patients with CMD. Further studies are necessary to validate these results and explore more personalized exercise strategies.

Supplementary material

Supplementary material is available at *European Journal of Preventive Cardiology*.

Acknowledgements

We express our sincere appreciation to the laboratory staff across all participating centres, as well as to the physicians and other healthcare professionals who were involved in CPET evaluations.

Author contribution

J.G.P.O.M.: conception and design, analysis and interpretation of the results, drafted the article. M.M.: analysis and interpretation of the results, revised it critically. F.V.C.M., G.F.B.C., and K.V.: interpretation of the results, revised it critically. M.W., T.M., F.D.'A., L.C., C.K., M.F., F.B., A.D.d.S., and V.C.: acquisition of data, revised it critically. G.C.J.: conception and design, analysis and interpretation of the results, revised it critically, supervision. D.H.: conception and design, analysis and interpretation of data, revised it critically, supervision. All authors provided their final endorsement and committed to being responsible for all facets of the work, ensuring its integrity and accuracy.

Funding

Financial support by the Special Research Fund (BOF) from Hasselt University/Belgium [BOF23DOCBL10 (J.G.P.O.M.) and BOF23KV10 (M.M.)] and from Flanders Research Foundation FWO, 1SE1222N (M.F.). This study was also supported by public research grants and scholarships from Brazilian fostering agencies: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior [CAPES (Coordination for the Advancement of Higher Education Personnel)], Conselho Nacional de Desenvolvimento Científico e Tecnológico [CNPq (National Council of Scientific and Technological Development)], and Fundação de Apoio a Pesquisa do Distrito Federal [FAPDF (The State Funding Agency of Distrito Federal)].

Conflict of interest: none declared.

Data availability

Data cannot be publicly shared due to legislative restrictions in certain participating countries. However, researchers who meet the criteria for accessing confidential data may request it upon reasonable inquiry.

References

1. Bunsawat K, Richardson RS. Sex as a biological variable in exercise prescription: a critical consideration in developing a road map for sex-related differences in cardiovascular research. *Am J Physiol Heart Circ Physiol* 2023;**324**:H126–H128.
2. Lindsey ML, LeBlanc AJ, Ripplinger CM, Carter JR, Kirk JA, Hansell Keehan K, *et al.* Reinforcing rigor and reproducibility expectations for use of sex and gender in cardiovascular research. *Am J Physiol Heart Circ Physiol* 2021;**321**:H819–H824.
3. Ansdell P, Thomas K, Hicks KM, Hunter SK, Howatson G, Goodall S. Physiological sex differences affect the integrative response to exercise: acute and chronic implications. *Exp Physiol* 2020;**105**:2007–2021.
4. Hansen D, Abreu A, Ambrosetti M, Cornelissen V, Gevaert A, Kemps H, *et al.* Exercise intensity assessment and prescription in cardiovascular rehabilitation and beyond: why and how: a position statement from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. *Eur J Prev Cardiol* 2022;**29**:230–245.
5. Iannetta D, Inglis EC, Mattu AT, Fontana FY, Pogliaghi S, Keir DA, *et al.* A critical evaluation of current methods for exercise prescription in women and men. *Med Sci Sports Exerc* 2020;**52**:466–473.
6. Milani JGPO, Milani M, Cipriano GFB, Hansen D, Cipriano Junior G. Exercise intensity domains determined by heart rate at the ventilatory thresholds in patients with cardiovascular disease: new insights and comparisons to cardiovascular rehabilitation prescription recommendations. *BMJ Open Sport Exerc Med* 2023;**9**:e001601.
7. Thomas HJ, Marsh CE, Lester L, Maslen BA, Naylor LH, Green DJ. Sex differences in cardiovascular risk factor responses to resistance and endurance training in younger subjects. *Am J Physiol Heart Circ Physiol* 2023;**324**:H67–H78.
8. D'Ascenzi F, Cavigli L, Pagliaro A, Focardi M, Valente S, Cameli M, *et al.* Clinician approach to cardiopulmonary exercise testing for exercise prescription in patients at risk of and with cardiovascular disease. *Br J Sports Med* 2022;**56**:1180–1187.
9. Milani JGPO, Milani M, Machado FVC, Wilhelm M, Marcin T, D'Ascenzi F, *et al.* Accurate prediction equations for ventilatory thresholds in cardiometabolic disease when gas exchange analysis is unavailable: development and validation. *Eur J Prev Cardiol* 2024;**31**:1914–1924.
10. O'Kelly AC, Michos ED, Shufelt CL, Vermunt JV, Minissian MB, Quesada O, *et al.* Pregnancy and reproductive risk factors for cardiovascular disease in women. *Circ Res* 2022;**130**:652–672.